AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05583747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
Study NCT05583747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
Study NCT06643247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
Study NCT06643247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
Study NCT05946876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S003 (A)
Description: IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study NCT05946876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (B)
Description: Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study NCT05819866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leriglitazone
Description: Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
Study NCT05819866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match the study drug visually and by taste
Study NCT05401422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: types
Study NCT05149079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod protein hydrolysate
Description: Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
Study NCT05149079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Whey protein powder, commercially available
Study NCT06314906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
Study NCT06314906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic Therapy
Description: Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
Study NCT06314906 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
Study NCT06314906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiemetic Therapy
Description: They will also receive the same antiemetic medications as the experimental group.
Study NCT05419154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early pain dependent weight-bearing without immobilization
Description: Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
Study NCT05353569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT Device(s)
Description: Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
Study NCT06067529 — intervention group
Intervention type: DRUG
Intervention: hormone replacement therapy
Description: hormone replacement therapy
Study NCT05665309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D anatomical model of aneurysm
Description: Surgery prepared with 3D anatomical model of aneurysm
Study NCT04716439 — intervention group
Intervention type: PROCEDURE
Intervention: Spine Surgery
Description: spine decompression and fixation
Study NCT06014905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized carbon C 13 pyruvate
Description: Given Intravenously (IV)
Study NCT06014905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image (MRI)
Description: Imaging procedure
Study NCT06014905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Given IV
Study NCT05920850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Video about LDCT lung cancer screening
Description: A culturally tailored video that provides education about the process LDCT lung cancer screening
Study NCT05920850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A culturally tailored shared decision-making tool
Description: A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
Study NCT05920850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flip chart
Description: The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
Study NCT05920850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Navigation support
Description: Navigation support for participants who express interest in LDCT and quitting smoking.
Study NCT05782413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical vestibular stimulation
Description: Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
Study NCT05782413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The design exercise program
Description: A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand
Study NCT05165329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
Description: PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
Study NCT05165329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
Description: PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
Study NCT05165329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.
Description: PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
Study NCT04739124 — intervention group
Intervention type: OTHER
Intervention: Follow-up questionnaires
Description: The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)
Study NCT04739124 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
Study NCT06521008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti muscarinic drugs
Description: a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
Study NCT06521008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions including bladder training
Description: The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
Study NCT06521008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training (PFMT)
Description: The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
Study NCT06521008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal exercise
Description: Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
Study NCT06521008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Training
Description: The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
Study NCT05875935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECoG : electrocorticography
Description: The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA).
Study NCT06119178 — intervention group
Intervention type: DEVICE
Intervention: EX-PRESS P-50 filtration device
Description: FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
Study NCT06119178 — intervention group
Intervention type: DEVICE
Intervention: EX-PRESS P-200 filtration device
Description: FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
Study NCT06511856 — intervention group
Intervention type: DEVICE
Intervention: ARROW
Description: Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
Study NCT06643247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
Study NCT05117125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heparin-binding protein
Description: Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Study NCT04860700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib hydrochloride
Description: Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study NCT05660369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Description: Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
Study NCT06200038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)
Description: Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist.
Study NCT06200038 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physical therapy and sham manual therapy
Description: A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist.
Study NCT06200038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physical therapy
Description: Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
Study NCT05095155 — intervention group
Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study NCT05140174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical Healing and Internalized Stigma (RHIS) Training
Description: 8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
Study NCT05951699 — intervention group
Intervention type: DEVICE
Intervention: minimally invasive preoperative image-guided vacuum-assisted biopsy
Description: minimally invasive preoperative image-guided vacuum-assisted biopsy of the breast and needle biopsy of axillary lymph node
Study NCT05587036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin oral tablet, 550 mg, twice daily, two-weeks
Study NCT04658719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camstent Coated Catheter
Description: The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
Study NCT04658719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Uncoated Foley Catheter
Study NCT05677867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (PF-07081532 20 mg plus 60 mg)
Description: Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
Study NCT05677867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (PF-07081532 80 mg)
Description: Formulation B: administered as a 80 mg immediate release tablet
Study NCT05826717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple
Description: 20g fructose in \[x\] g of apple
Study NCT05826717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed apple
Description: 20g fructose in \[x\] g of mashed apple
Study NCT05826717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice
Description: 20g fructose in \[x\] ml apple juice
Study NCT05826717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose powder in water
Description: 20g fructose in \[x\] ml water
Study NCT05995522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: 100 µg per day for 90 days
Study NCT05995522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: 500 mg per day for 90 days
Study NCT06351215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone group
Description: 5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
Study NCT06351215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill that is identical look-alike to study drug
Study NCT05463679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin
Description: 500 mg QD orally in the form of four 125 mg tablets with background standard of care
Study NCT05463679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
Study NCT04770597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aranet4 Home CO2 monitor
Description: The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
Study NCT04770597 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aranet4 Home CO2 monitor
Description: The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.